Mersana Therapeutics (MRSN) Set to Announce Quarterly Earnings on Thursday

Mersana Therapeutics (NASDAQ:MRSN) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $22.59 million. Mersana Therapeutics had a negative net margin of 465.80% and a negative return on equity of 282.36%. Mersana Therapeutics’s revenue for the quarter was down 27.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.44) EPS. On average, analysts expect Mersana Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mersana Therapeutics Trading Up 0.7 %

Shares of Mersana Therapeutics stock opened at $3.53 on Wednesday. Mersana Therapeutics has a twelve month low of $0.80 and a twelve month high of $9.62. The company has a quick ratio of 3.36, a current ratio of 3.36 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $4.32 and a 200-day moving average price of $3.08. The firm has a market cap of $427.58 million, a price-to-earnings ratio of -2.35 and a beta of 1.61.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. JPMorgan Chase & Co. raised Mersana Therapeutics from an “underweight” rating to a “neutral” rating and set a $5.00 price objective on the stock in a research note on Tuesday, March 19th. Wedbush upgraded shares of Mersana Therapeutics from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $2.00 to $7.00 in a research report on Thursday, February 29th. Truist Financial upgraded shares of Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a research report on Thursday, February 29th. BTIG Research raised shares of Mersana Therapeutics from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a report on Thursday, February 29th. Finally, Robert W. Baird boosted their price objective on Mersana Therapeutics from $1.00 to $5.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.29.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.